Overview
NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because no evidence submission was received from Bristol–Myers Squibb.
Last reviewed: 13 March 2019
Next review: We will review this decision if the company decides to make a submission.